Potentiated AV conduction time & increased negative inotropic effect w/ class I antiarrhythmics (quinidine, hydroquinidine, cibenzoline, flecainide, disopyramide, lidocaine, mexiletine, propafenone); class III antiarrhythmic drugs (amiodarone). Negative influence on contractility & AV conduction w/ Ca channel antagonists of verapamil/diltiazem type. Profound hypotension & AV block w/ IV verapamil. Worsened heart failure by a decrease in central sympathetic tones (reduction of heart rate & cardiac output, vasodilation) w/ centrally-acting antihypertensives (clonidine, guanfacine, moxonidine, methyldopa, rilmenidine). Attenuated reflex tachycardia & increased risk of hypotension w/ anaesth. Increased fall in BP w/ baclofen (antispastic agent), amifostine (antineoplastic adjunct). Increased AV conduction time w/ digitalis glycosides. Increased risk of hypotension, & further deterioration of ventricular pump function in patients w/ heart failure w/ Ca antagonists of the dihydropyridine type (amlodipine, felodipine, lacidipine, nifedipine, nicardipine, nimodipine, nitrendipine). Enhanced hypotensive effect w/ antipsychotics, antidepressants (TCAs, barbiturates & phenothiazines). Risk of HTN, severe bradycardia & heart block w/ sympathomimetic agents. Increased plasma levels w/ CYP2D6 inhibitors eg, paroxetine, fluoxetine, thioridazine & quinidine.